Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Finished Goods data on file, last reported at $22.0 million in Q1 2026.

• Quarterly Finished Goods fell 4.84% year-over-year to $22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.0 million (down 4.84% YoY) and the FY2025 annual result came in at $25.0 million, up 8.7% from the prior year.
• Finished Goods fell to $22.0 million in Q1 2026 per RARE's latest filing, from $25.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $26.7 million in Q2 2025 and bottomed at $4.9 million in Q2 2022.
• The 5-year median for Finished Goods is $14.9 million (2024), against an average of $15.8 million.
• The widest annual swing landed in 2022, when Finished Goods declined 13.08%; it then soared 107.99% in 2023.
• Tracing RARE's Finished Goods over 5 years: stood at $9.3 million in 2022, then soared by 62.82% to $15.1 million in 2023, then soared by 52.22% to $23.0 million in 2024, then gained by 8.7% to $25.0 million in 2025, then slipped by 12.0% to $22.0 million in 2026.
• Per Business Quant, the three latest RARE Finished Goods figures stand at $22.0 million (Q1 2026), $25.0 million (Q4 2025), and $23.0 million (Q3 2025).

Peer Comparison